XZXiaozhou Zhou

Xiaozhou Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiaozhou Zhou has a total of 82 co-authors. Here are the top co-authors by number of shared publications:

  • Rui Hu

    Department of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, P.R. China

    27 shared publications
  • Jing Li

    Department of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, P.R. China

    23 shared publications
  • Qi Huang

    Department of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, P.R. China

    23 shared publications
  • Wenxing Feng

    Department of Liver Disease, The Fourth Clinical Medical School, Guangzhou University of Chinese Medicine, Shenzhen, China

    21 shared publications
  • Xin Zhong

    Department of Liver Disease Shenzhen Traditional Chinese Medicine Hospital Shenzhen Guangdong China

    21 shared publications
  • Zhiyi Han

    Department of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, P.R. China

    19 shared publications

Latest Publications

  • Open Access

    Adverse Event Reporting Patterns Associated with Concomitant Use of 5-HT3 and NK-1 Receptor Antagonists: A Large-Scale Spontaneous-Reporting Analysis

    by Ruiqi Zhao, Shiqi Tang, Mengyao Han, Hui Hu, Jiesheng Guo, Minling Lv, Jialing Sun, Xiaozhou Zhou

    Background/Objectives: Chemotherapy-induced nausea and vomiting (CINV) is common and compromises quality of life and adherence. 5-HT3 receptor antagonists (RAs) and NK-1 RAs are cornerstones, yet adverse event patterns associated with their concomitant use are not well characterized. Methods: We queried the US Food and Drug Administration Adverse Event Reporting System (FAERS) from 2004 Q1–2025 Q1 and deduplicated reports per Food and Drug Administration (FDA) guidance. Five algorithms—the Ω shrinkage measure, additive model, multiplicative model, combination risk ratio, and chi-square model—detected disproportionate reporting signals associated with concomitant use. We also performed time-to-onset (TTO) analysis and logistic regression. Results: We identified 965 concurrent use cases with a mean age of 58 years and a mean weight of 70 kg, with 59.7% (n = 575) of these cases being female. These reports included 366 preferred terms (PTs). Forty-nine PTs were significant across all five algorithms, mainly skin and subcutaneous disorders, hypersensitivity reactions, blood pressure abnormalities, hepatic and renal impairment, and nervous system disorders, with additional signals for abnormal antidiuretic hormone secretion, respiratory disorders, and oropharyngeal disorders. TTO showed most adverse drug events (ADEs) occurred within 20 days of therapy initiation. Logistic regression indicated that older age was associated with higher odds of classification as an important medical event (IME). Conclusions: Beyond prescribing information, we detected previously unrecognized adverse event terms that were disproportionately reported with concomitant use and that merit attention in practice.


  • Open Access

    Deciphering the Genetic Underpinnings of Liver Cirrhosis–Heart Failure Comorbidity Through Multi-Omics: CRIM1 as a Key Endothelial Mediator

    by Ruiqi Zhao, Jiesheng Guo, Mengyao Han, Shiqi Tang, Hui Hu, Mengqing Ma, Jialing Sun, Xiaozhou Zhou

    The co-occurrence of liver cirrhosis (LC) and heart failure (HF) poses considerable clinical challenges, yet the cellular and molecular determinants of this comorbidity remain poorly characterized. To address this, we developed an integrative multi-omics pipeline encompassing GWAS meta-analysis, gsMap-based spatial transcriptomic projection, GeneEnrich functional annotation, single-cell atlas construction, seismicGWAS and ECLIPSER cell-type scoring, eCAVIAR and fastenloc colocalization, hdWGCNA network inference, scTenifoldKnk in silico gene perturbation, and GCTA-COJO fine-mapping. Quality-controlled meta-analysis yielded 12,347,758 and 9,256,862 variant-level associations for LC and HF, respectively. Spatial projection confirmed preferential enrichment of disease signals within embryonic hepatic and cardiac compartments. Pathway analyses disclosed that LC-linked loci were concentrated in lipid metabolic programs, whereas HF-linked loci implicated mitochondrial bioenergetics and lysosomal degradation. At the cellular level, endothelial cells emerged as the dominant HF-associated population. Convergent evidence from five orthogonal algorithms pinpointed CRIM1 as the sole robustly supported shared gene, selectively enriched in HF endothelial cells; virtual perturbation further identified LCP1 and PTPRC as downstream regulatory nodes. Fine-mapping of the chromosome 2 locus harboring rs12476437 revealed multiple statistically independent signals in the vicinity of CRIM1. Collectively, these findings computationally prioritize the endothelial–CRIM1 axis as a previously unappreciated candidate mechanistic bridge between LC and HF requiring experimental validation.

  • Open Access

    AI-Powered Marine Drug Discovery: A Putative Dual c-Met/VEGFR2 Lead Candidate for Hepatocellular Carcinoma via Deep Learning and Multiscale Simulation

    by Ruiqi Zhao, Yuhan Wang, Mengyao Han, Jiesheng Guo, Hui Hu, Shiqi Tang, Mengqing Ma, Xiaozhou Zhou, Jialing Sun

    Background: Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality. The c-Met and VEGFR2 pathways synergistically drive HCC progression. Marine natural products offer chemically diverse drug reservoirs; however, conventional activity-guided isolation faces labor intensity, low throughput, and frequent compound rediscovery, limiting marine drug development. Objective: To pioneer an artificial intelligence-driven marine drug discovery workflow integrating deep learning virtual screening for identifying dual c-Met/VEGFR2 promising in silico candidate from marine natural product repositories. Methods: UniSite predicted binding pockets in c-Met (PDB: 4R1V) and VEGFR2 (PDB: 2XIR). Drug-likeness filtering of 695,000 compounds from COCONUT and CMNPD databases yielded 84,730 candidates. DiffDock-based screening identified dual-target binders, validated through 200 ns molecular dynamics simulations, MM-GBSA calculations, and DFT analyses. Results: The marine phthalide CMNPD30506 [(S)-3-ethyl-5,6-dihydroxyphthalide] emerged as the lead candidate, engaging VEGFR2 via four hydrophobic contacts and one π-cation interaction with LYS868, while binding c-Met through four hydrophobic interactions, two hydrogen bonds, and π-π stacking. Molecular dynamics demonstrated stable RMSD profiles and dynamic hydrogen bond enrichment. MM-GBSA revealed binding free energies of −14.79 and −13.28 kcal/mol for VEGFR2 and c-Met, respectively, driven by van der Waals forces. DFT calculations indicated a HOMO-LUMO gap of 2.410 eV. Conclusions: This AI-augmented workflow successfully identified CMNPD30506 as a promising dual c-Met/VEGFR2 HCC therapeutic from marine libraries, overcoming traditional discovery bottlenecks through integrated deep learning and physics-based simulations, exemplifying AI’s potential in marine pharmacological research.

  • Open Access

    Association between thyroid feedback quartile index and FIB-4-defined fibrosis risk in patients with metabolic dysfunction-associated steatotic liver disease, type 2 diabetes mellitus, and treated primary hypothyroidism: an exploratory cross-sectional study

    by Yuhan Wang, Jicheng Xie, Yan Wang, Xingning Liu, Xiaozhou Zhou

    Background: Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) frequently coexists with Type 2 Diabetes Mellitus (T2DM) and Primary Hypothyroidism (PH); nevertheless, the relationship between thyroid hormone sensitivity and FIB-4-defined fibrosis risk across these metabolic diseases is yet unknown. Methods: In 102 patients with MASLD, MASLD+T2DM, and MASLD+T2DM+treated PH (34 per group), this exploratory cross-sectional study examined the association between the Thyroid Feedback Quantile Index (TFQI) and the Fibrosis-4 Index (FIB-4). The cumulative distribution functions of TSH and FT4 were used to calculate TFQI. A surrogate indicator of the risk of fibrosis was FIB-4. G*Power 3.1.9.7 was used for post-hoc power analysis after multivariable regression and correlation analyses were completed. Results: In the MASLD-alone group, TFQI and FIB-4 had a significant inverse correlation in unadjusted analysis ( r = −0.384, P = 0.025). Nevertheless, after controlling for age, sex, and BMI, this link was diminished and no longer significant ( β = −0.195, P = 0.073). The most powerful independent predictor of FIB-4 was age ( β = 0.704, P < 0.001). Age significantly confounded the association, according to sensitivity analyses such as age-adjusted partial correlation, FIB-4 component analysis, and FIB-4 category analysis. In the other two groups, no noteworthy correlations were found. Conclusions: Age played a major role in explaining the inverse correlation between TFQI and FIB-4 in patients with MASLD alone in this exploratory study. These results should be considered hypothesis-generating and should be validated in bigger prospective trials with direct measurements of fibrosis. Future research may benefit from the heterogeneous associations across metabolic backgrounds.

  • Open Access

    Gene‐Based Clustering Identifies QSOX1 and IL1RAP as Biomarkers of Metabolic Dysfunction‐Associated Steatotic Liver Disease

    by Wenfeng Ma, Jinrong Huang, Benqiang Cai, Mumin Shao, Xuewen Yu, Mikkel Breinholt Kjær, Minling Lv, Xin Zhong, Shaomin Xu, Bolin Zhan, et al.

    Background and Aims: Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a progressive liver disease that ranges from simple steatosis to inflammation, fibrosis and cirrhosis. To address the unmet need for new MASLD biomarkers, we aimed to identify candidate biomarkers using publicly available RNA sequencing (RNA‐seq) and proteomics data. Methods: An approach involving unsupervised gene clustering was performed using homogeneously processed and integrated RNA‐seq data of 625 liver specimens to screen for MASLD biomarkers, in combination with public proteomics data from healthy controls and MASLD patients. Additionally, we validated the results in the MASLD and healthy cohorts using enzyme‐linked immunosorbent assay (ELISA) of plasma and immunohistochemical staining (IHC) of liver samples. Results: We generated a database ( https://dreamapp.biomed.au.dk/NAFLD/ ) for exploring gene expression changes along MASLD progression to facilitate the identification of genes and pathways involved in the disease's progression. Through cross‐analysis of the gene and protein clusters, we identified 38 genes as potential biomarkers for MASLD severity. Up‐regulation of Quiescin sulfhydryl oxidase 1 ( QSOX1 ) and down‐regulation of Interleukin‐1 receptor accessory protein ( IL1RAP ) were associated with increasing MASLD severity in RNA‐seq and proteomics data. Particularly, the QSOX1/IL1RAP ratio in plasma demonstrated effectiveness in diagnosing MASLD, with an area under the receiver operating characteristic (AUROC) of up to 0.95 as quantified by proteomics profiling and an AUROC of 0.82 with ELISA. Conclusions: We discovered a significant association between the levels of QSOX1 and IL1RAP and MASLD severity. Furthermore, the QSOX1/IL1RAP ratio shows promise as a non‐invasive biomarker for diagnosing MASLD and assessing its severity.

  • Open Access

    Deep Learning-Based Virtual Screening Identifies Potential Small-Molecule Inhibitors of ASK1: Natural Product Lead Discovery for MASH

    by Ruiqi Zhao, Jiahua Yang, Mengyao Han, Shiqi Tang, Hui Hu, Jiesheng Guo, Mengqing Ma, Jialing Sun, Xiaozhou Zhou

    Apoptosis signal-regulating kinase 1 (ASK1) represents a critical therapeutic target for metabolic dysfunction-associated steatohepatitis (MASH). Natural products, owing to their unique chemical diversity, constitute a rich reservoir for discovering novel ASK1 inhibitors. The emergence of artificial intelligence-assisted drug discovery (AIDD) has opened new avenues for exploring small-molecule inhibitors. Through virtual screening, molecular docking, interaction profiling, molecular dynamics simulations, and MM-GBSA binding free energy calculations, we systematically evaluated the binding mode, stability, and key residue contributions of the CMNPD10921–ASK1 complex. CMNPD10921 stably occupied the ASK1 active pocket, forming hydrophobic interactions and hydrogen bonds with multiple key amino acid residues. MM-GBSA analysis yielded a total computed binding free energy of −31.15 kcal/mol, suggesting a computationally favorable interaction, with van der Waals forces serving as the dominant energetic driver of complex stabilization. Residue energy decomposition further identified ILE324, THR288, and THR639 as major contributors to ligand binding. Integrating deep learning, molecular simulation, and quantum chemical calculations, this study successfully identified CMNPD10921 from a vast natural product library as a putative lead compound candidate targeting the ASK1 central regulatory region, offering a novel candidate molecule for anti-MASH drug development.

  • Open Access

    Multi-Omics Integrative Analysis Identifies the NK Cell–STAT3 Axis as a Shared Immunogenetic Hub Underlying the Comorbidity of Primary Sclerosing Cholangitis and Ulcerative Colitis

    by Ruiqi Zhao, Mengyao Han, Bei Zhang, Mengqing Ma, Kongli Fan, Jing Li, Jialing Sun, Xiaozhou Zhou

    Primary sclerosing cholangitis (PSC) and ulcerative colitis (UC) exhibit a striking clinical comorbidity, with 60–80% of PSC patients concurrently harboring UC, yet the shared immunogenetic mechanisms remain poorly understood. Here, we constructed a multi-omics integrative framework to systematically dissect the cellular and molecular basis of this comorbidity. GWAS meta-analyses were performed for each disease, followed by tissue-level enrichment assessment using QTLEnrich, MAGMA, and gsMap spatial mapping. Single-cell transcriptomic atlases were constructed, and cell-type prioritization was conducted using four complementary methods. Core genes were identified through cross-validation of five algorithms, with subsequent genomic fine-mapping via FUMA and GCTA-COJO. Tissue-level analyses consistently identified the intestine and immune-related tissues as commonly affected. Multi-dimensional evidence integration prioritized natural killer (NK) cells as the core effector cell type for both diseases, supported principally by CELLECT (Cell-type Expression-specific Integration for Complex Traits) heritability enrichment and single-cell differential analysis. Convergence of five gene-level algorithms pinpointed STAT3 as the sole high-confidence comorbidity gene, broadly expressed across immune cell populations and exhibiting tissue-differential alternative splicing. Colocalization identified a high-risk variant (rs3736161) within the STAT3 locus, with conditional analysis revealing 35 additional independent signals. These findings identify the NK cell–STAT3 axis as a central immunogenetic hub connecting PSC and UC, offering potential therapeutic targets for comorbidity management.


  • Open Access

    Computational Discovery of Dual-Target LDHA/BRD4 Inhibitors Targeting the Lactate–Kla–B7-H3 Immunosuppressive Axis Through AI-Driven Virtual Screening

    by Ruiqi Zhao, Mengyao Han, Bei Zhang, Mengqing Ma, Xiaozhou Zhou, Jialing Sun

    Background/Objectives: Immune evasion remains a critical barrier to effective hepatocellular carcinoma (HCC) therapy. Lactate dehydrogenase A (LDHA) drives lactate accumulation and histone lysine lactylation (Kla), reshaping the immunosuppressive microenvironment, while bromodomain-containing protein 4 (BRD4) sustains B7-H3 transcription via super-enhancer occupancy. Despite their synergistic roles in the lactate–Kla–B7-H3 immunosuppressive axis, no dual-target inhibitor simultaneously engaging both proteins has been reported. This study aimed to discover dual LDHA/BRD4 inhibitors from natural product libraries using an integrated AI-driven computational pipeline. Methods: We established a multi-tier virtual screening cascade comprising Lipinski/QED drug-likeness filtration, DiffDock-based AI docking, QuickVina binding energy validation, PLIP interaction profiling, 200 ns all-atom molecular dynamics simulations, MM-GBSA binding free energy calculations, and density functional theory analysis. Natural product libraries from COCONUT and CMNPD databases (84,730 compounds post-filtration) were screened against both targets. Results: High-throughput DiffDock screening identified 11 dual-target hits, from which CNP0038114.1 and CMNPD16582 emerged as prioritized lead candidates. All four protein–ligand complexes maintained structural stability throughout MD simulations, with MM-GBSA binding free energies ranging from −27.24 to −32.45 kcal/mol, predominantly driven by van der Waals interactions. DFT calculations revealed distinct electronic profiles: CNP0038114.1 exhibited a narrow HOMO–LUMO gap (2.718 eV) favoring charge-transfer reactivity, whereas CMNPD16582 displayed a larger gap (4.822 eV), suggesting superior chemical stability. Conclusions: This computational study furnishes two novel natural product leads for targeting the lactate–Kla–B7-H3 immunosuppressive axis in HCC, establishing a generalizable AI-driven workflow for dual-target inhibitor discovery.